Advertisement
Singapore markets close in 3 hours 18 minutes

  • Straits Times Index

    3,308.85
    +8.85 (+0.27%)
     

  • Nikkei

    38,626.03
    -6.99 (-0.02%)
     

  • Hang Seng

    18,050.95
    -284.37 (-1.55%)
     

  • FTSE 100

    8,272.46
    +67.35 (+0.82%)
     

  • Bitcoin USD

    64,559.81
    -811.82 (-1.24%)
     

  • CMC Crypto 200

    1,352.05
    -30.61 (-2.21%)
     

  • S&P 500

    5,473.17
    -13.86 (-0.25%)
     

  • Dow

    39,134.76
    +299.90 (+0.77%)
     

  • Nasdaq

    17,721.59
    -140.64 (-0.79%)
     

  • Gold

    2,376.70
    +7.70 (+0.33%)
     

  • Crude Oil

    82.34
    +0.17 (+0.21%)
     

  • 10-Yr Bond

    4.2540
    +0.0370 (+0.88%)
     

  • FTSE Bursa Malaysia

    1,596.24
    +3.55 (+0.22%)
     

  • Jakarta Composite Index

    6,933.09
    +113.77 (+1.67%)
     

  • PSE Index

    6,229.76
    -114.80 (-1.81%)
     

Olema Oncology to Participate in Upcoming Investor Conferences in June

Olema Oncology
·1-min read
Olema Oncology
Olema Oncology

SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences:

Jefferies Global Healthcare Conference 
Date: Wednesday, June 5, 2024, at 2:00 p.m. ET
Location: Marriott Marquis in New York, NY
Format: Fireside Chat

Goldman Sachs 45th Annual Global Healthcare Conference 
Date: Wednesday, June 12, 2024, at 11:20 a.m. ET
Location: Loews Miami Beach Hotel in Miami, FL
Format: Fireside Chat

ADVERTISEMENT

Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.

Contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications
ir@olema.com